登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07827261,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Toxicity from prior antitumor therapy has recovered to ≤Grade 1 as defined by NCI-CTCAE v6.0;
入选标准第 9 条
Prior treatment with drugs targeting KRAS G12C;
排除标准第 1 条
ECOG performance status score ≤1;
入选标准第 8 条
Coagulation function: international normalized ratio ≤1.5, and activated partial thromboplastin time ≤1.5×ULN;
入选标准第 12 条
Must have at least one measurable lesion as defined by RECIST v1.1;
入选标准第 7 条
Diagnosis of active malignancy within 5 years before randomization in the study;
排除标准第 14 条
Pregnant or breastfeeding women;
排除标准第 27 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07827261,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily sign the informed consent form and comply with protocol requirements; No restriction on gender; Age ≥18 years and ≤75 years; Expected survival time ≥3 months; Patients with locally advanced or metastatic non-small cell lung cancer; Agree to provide archived tumor tissue specimens from the primary or metastatic lesion within 2 years, or fresh tissue samples; Must have at least one measurable lesion as defined by RECIST v1.1; ECOG performance status score ≤1; Toxicity from prior antitumor therapy has recovered to ≤Grade 1 as defined by NCI-CTCAE v6.0; No severe cardiac dysfunction, with left ventricular ejection fraction ≥50%; Organ function levels must meet the requirements; Coagulation function: international normalized ratio ≤1.5, and activated partial thromboplastin time ≤1.5×ULN; Urine protein ≤1+ or <1000 mg/24 h; For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment; serum pregnancy testing must exclude pregnancy, and the patient must be non-lactating; all enrolled patients (regardless of male or female) should use adequate barrier contraception throughout the entire treatment period and for 7 months after treatment completion.排除标准:Exclusion Criteria:
Prior treatment with drugs targeting KRAS G12C; Prior use of ADC drugs with small-molecule toxins as topoisomerase I inhibitors; Coexisting other known oncogenic driver gene mutations that can be targeted therapeutically; Prior history of intestinal disease or major gastric surgery; Participation in any other clinical trial within 4 weeks before the first administration of this trial; History of severe heart disease or cerebrovascular disease; Receipt of radical radiotherapy, major surgery, extensive radiotherapy, etc., within 4 weeks before randomization in the study; Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; QTc interval prolongation, complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmias; History of interstitial lung disease/interstitial pneumonia treated with steroids, etc.; Concurrent pulmonary disease leading to clinically severe impairment of respiratory function; Severe infection occurring within 4 weeks before randomization in the study; Patients at risk of active autoimmune disease, or patients with a history of autoimmune disease; Diagnosis of active malignancy within 5 years before randomization in the study; Positive human immunodeficiency virus antibody, active tuberculosis, active syphilis, active hepatitis B virus infection, or hepatitis C virus infection; Hypertension poorly controlled with two antihypertensive drugs; Patients with poorly controlled blood glucose; Presence of a large amount of serous cavity effusion, or serous cavity effusion with obvious symptoms caused by the serous cavity effusion, etc.; Active central nervous system metastasis; Imaging examination suggesting that the tumor has invaded or encased the abdomen, chest, etc.; Severe and unhealed wounds, ulcers, or fractures within 4 weeks before signing informed consent; Trial participants with clinically obvious bleeding or a clear bleeding tendency within 4 weeks before signing informed consent; History of allogeneic stem cell, bone marrow, or organ transplantation; Patients with a history of allergy to recombinant humanized antibodies or allergy to any excipient component of BL-B01D1; History of severe neurological or psychiatric disease; History of autologous or allogeneic stem cell transplantation; Pregnant or breastfeeding women; Trial participants planning to receive vaccination or who received a live vaccine within 28 days before randomization in the study; Other circumstances in which the investigator considers it inappropriate to participate in this clinical trial.
引自 ClinicalTrials.gov, NCT07827261, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07827261,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。